Transgene SA · EURONEXT:TNG

Transgene SA — Rodman & Renshaw (May 2005)

28 slides from Transgene SA's conference presentation, May 4, 2005

  1. Slide 1: Transgene: New management – New strategy – New future

    TRANSGENE New management – New strategy – New future Rodman & Renshaw - May 4, 2005 1 transgene

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains forward-looking statements, including statements regarding Transgene’s capital requirements and prospects. Statements that are not historical facts are based on the Company's current expectations, beliefs, estimates, forecasts and assumptions. The

  3. Slide 3: Agenda

    Agenda § INTRODUCTION § TRANSGENE STRATEGIC DIRECTION • Transgene transformed • Transgene in 2007 • Short term objectives § THE CLINICAL PIPELINE • The pipeline today • New clinical data § 2004 FINANCIAL RESULTS § CONCLUSION 3 transgene

  4. Slide 4: Transgene Transformed

    Transgene Transformed §December, 2004: New CEO with strong biotech experience and track record §February, 2005: New CSO with impressive background in immunology and oncology. §February, 2005: Strong Phase II data in lung and prostate cancers §March, 2005: Company refocused on immunotherapy to treat

  5. Slide 5: The future -- Transgene in 2007

    The future -- Transgene in 2007 -- § Three Phase III trials ongoing: • MVA-Muc1-IL2 to treat NSCLC • MVA-HPV-IL2 in CIN2/3 related to HPV16 • Ad-IFNg to treat cutaneous T cell lymphoma (CTCL) § MVA Muc1-IL2 in Prostate in Phase IIb § MVA-HCV in Phase II to treat chronic carriers § Partnerships for t

  6. Slide 6: 2005 Clinical Development Plan

    2005 Clinical Development Plan Indication Preclinical Phase I Phase II Next step MVA-MUC1-IL2 Lung Phase IIb MVA-HPV-IL2 CIN 2/3 (6 month follow up) Phase IIb Ad-IFNγ Cutaneous T-Cell Lymphoma (CTCL) Phase II / III MVA-HCV Hepatitis C Phase I / II Myodys® Duchenne / Becker muscular dystrophy AFM Pha

  7. Slide 7: Short Term Objectives

    Short Term Objectives § Completion of organizational refocusing to achieve clinical proof of concept ASAP § Re-deploy research programs to support product strategy • Development of cancer & infectious disease drug candidates • Broadening technology platforms beyond viral vectors § Leverage internal

  8. Slide 8: Latest Clinical Developments

    Latest Clinical Developments 8 transgene

  9. Slide 9: MVA-MUC1-IL2 Product profile

    MVA-MUC1-IL2 Product profile § Recombinant MVA (Modified Virus Ankara) • non-replicative, highly immunogenic poxvirus § Expressing MUC1 tumor-associated antigen • MUC1 is found in most adenocarcinoma • Associated with poor prognosis Cell membrane § Expressing human IL-2 cDNA GalNAc Sialic Ac (Tn) ST

  10. Slide 10: MVA-MUC1-IL2 Phase II Interim Results

    MVA-MUC1-IL2 Phase II Interim Results § Interim Results (February 2005) § End points reached in Non Small-cell Lung Cancer MVA-Muc1-IL2 + chemo : 35 evaluable patients 13/35 (37%) PR (validated by central reading) 11/35 (31%) SD > 12w 24/35 (68%) Clinical benefit Time to Progression 6.4 months Overa

  11. Slide 11: MVA-MUC1-IL2 in NSCLC: Comparison With Published Clinical Studies

    MVA-MUC1-IL2 in NSCLC : Comparaison With Published Clinical Studies Using Navelbine / Cisplatine regimen Study % response Study TTP Study Overall survival (months) (months) Gebbia 44 MVA-Muc1-IL2 + 6.4 MVA-Muc1-IL2 + >12 MVA-Muc1-IL2 + 37 % chemo chemo chemo Gridelli 5.3 Fossela 10.1 Souquet 34.6 Fo

  12. Slide 12: MVA-MUC1-IL2 Future direction

    MVA-MUC1-IL2 Future direction § Final Phase II data presentation at ASCO (13-17 May 2005) § Next step: to demonstrate clinical benefit in lung cancer patients through a 150 patients randomized Phase IIb controlled study evaluating the combination of MVA-MUC1-IL2 to standard chemotherapies versus che

  13. Slide 13: MVA-HPV-IL2 Product profile

    MVA-HPV-IL2 Product profile § Recombinant MVA (Modified Virus Ankara) • non-replicative, highly immunogenic poxvirus § Expressing early genes of Human Papilloma Virus 16 (HPV16) • CIN (cervical intraepithelial neoplasia) due to HPV: pre-cancerous stage of cervix cancer • “HPV is the necessary cause

  14. Slide 14: MVA-HPV-IL2 Clinical Trial Design - Completed Phase II

    MVA-HPV-IL2 Clinical Trial Design - Completed Phase II § Multicenter study in France § CIN2/3 in HPV16+ patients § 3 sub-cutaneous injections of MVA-HPV-IL2, on Days 1-8-15 § 2 doses tested: 5x105 pfu and 5x107 pfu § Standard treatment (conisation) on Week 6-8 14 transgene

  15. Slide 15: MVA-HPV-IL2 Final Results of Completed Phase II

    MVA-HPV-IL2 Final Results of Completed Phase II Summary table of MVA-HPV-IL2 dose (pfu) secondary efficacy endpoints 5x105 5x107 Patients treated 14 17 Patients analyzed for efficacy 13 16 Viral clearance 0 4 Partial regression of histology signs 0 5 Reduction of grade (to CIN1) 0 2 Limited extent o

  16. Slide 16: MVA-HPV-IL2 Clinical Trial Design - Phase IIb - Ongoing

    MVA-HPV-IL2 Clinical Trial Design - Phase IIb - Ongoing § CIN2/3 in HPV 16-positive patients § Study design • Open-label, 5x107 pfu • 18 CIN2/3 patients § Treatment plan • Up to 6-month assessment period to study efficacy • Follow-up every 2 months : Cytology + virology + colposcopy ± biopsy • Respo

  17. Slide 17: Ad-IFNγ Product Profile

    Ad-IFNγ Product Profile § Recombinant adenovirus vector containing the sequence coding for the human IFN-g § Mechanism of action • Direct action on tumor cells: antiproliferative, induction of apoptosis • Indirect actions on tumors: immune stimulation, antiangiogenic activities § Clinical positionin

  18. Slide 18: Ad-IFNγ Clinical Trial Design

    Ad-IFNγ Clinical Trial Design Phase I/II : Primary Cutaneous Lymphoma § Study design Dose escalation 3 dose levels 3.109 tp → 3.1011 tp 3 patients / dose level (Phase I) + 9 patients at highest dose + up to 18 patients (Phase I / II) § Treatment plan Intra-tumoral administration Weekly injections (D

  19. Slide 19: Ad-IFNγ Efficacy Results – February 28, 2005

    Ad-IFNγ Efficacy Results – February 28, 2005 § Interim data first 20 patients • Clinical responses observed locally 7 CR and 3 PR out of 18 evaluable patients (56%) • Distant clinical responses : 2 CR – 1 PR out of 12 evaluable patients • Overall response rate (53%) 19 transgene

  20. Slide 20: Ad-IFNγ Future Direction

    Ad-IFNγ Future Direction § Clinical development Cutaneous Lymphoma: • Phase II / III study (Q1 06 – Q1 08) in CTCL patients • Placebo controlled – 2 step study – 75 patients § Regulatory strategy : • U.S.: • IND preparation and filing in process • Orphan drug designation submission Q4 05 • E.U.: • P

  21. Slide 21: Phase I & Preclinical Pipeline

    Phase I & Preclinical Pipeline § MVA-HCV monotherapy • Chronic carriers (naïve and non-responders) • Start US Phase I/II trials in Q1 2006 • Phase II expected to begin by early 2007 • Prime-boost combinations under investigation in preclinicals. § Duchenne muscular dystrophy • First ever gene based

  22. Slide 22: Financial Information

    FINANCIAL INFORMATION 22 transgene

  23. Slide 23: Statement of Operations

    Statement of Operations US GAAP; in € million ; unaudited 2004 Revenues 2.5 Operating expenses (24.2) R&D (20.0) G&A (4.2) Loss from operations (21.7) Interest income 0.5 Income tax benefit 0.7 Net loss (20.5) Cash 14.6 2004 burn rate: 20.3 M€ 2005 expected burn rate: 20.0 M€ 23 transgene

  24. Slide 24: Conclusion

    CONCLUSION 24 transgene

  25. Slide 25: Milestones and Newsflow

    Milestones and Newsflow PRODUCT INDICATION MILESTONE DATE Asco presentation of results for Lung & Prostate Q2 2005 MVA-MUC1-IL2 NSCLC / Lung Start of Phase IIb trial Q4 2005 MVA-HPV-IL2 CIN 2/3 Results on Phase II trial Q4 2005 Feedback on IND review Q2 2005 Ad-IFNg CTCL Final results on 36 patients

  26. Slide 26: Investment Case

    Investment Case § Clinical pipeline with 3 phase II in active development § Products with large market potential aiming at fullfilling large unmet medical needs § Focused strategy in therapeutic vaccine field, leading to rich newsflow in 2005 § Large reservoir of opportunities (internal product cand

  27. Slide 27: Senior Management

    Senior Management Dr. Christophe MERIEUX Philipe ARCHINARD Chairman Chief Executive Officer Philippe PONCET Jean-Yves BONNEFOY Chief Scientific Officer Chief Financial Officer 27 transgene

  28. Slide 28: Transgene contact details

    Transgene 11 rue de Molsheim 67082 Strasbourg Cedex France Contact : communication@transgene.fr Tel : +33-(0)3.88.27.91.02 Web Site : www.transgene.fr 28 transgene

Transgene — Rodman & Renshaw (May 2005) on 6ix